Although the intriguing connection between KRAS genotype and FcRn expression level remains blurred, the two critical regulators of albumin metabolism have demonstrated synergistic impacts on the sensitivity of pancreatic cancer to albumin-conjugated drugs both in vitro and in vivo. This evidence concerns the gene ALB and pancreatic neoplasm.